Detalhe da pesquisa
1.
Hepatic Activin E mediates liver-adipose inter-organ communication, suppressing adipose lipolysis in response to elevated serum fatty acids.
Mol Metab
; 78: 101830, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-38787338
2.
Pharmacological inhibition of Kv1.3 fails to modulate insulin sensitivity in diabetic mice or human insulin-sensitive tissues.
Am J Physiol Endocrinol Metab
; 301(2): E380-90, 2011 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-21586699
3.
Dual-acting peptide with prolonged glucagon-like peptide-1 receptor agonist and glucagon receptor antagonist activity for the treatment of type 2 diabetes.
J Endocrinol
; 192(2): 371-80, 2007 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-17283237
4.
Engineering of a VPAC2 receptor peptide agonist to impart dipeptidyl peptidase IV stability and enhance in vivo glucose disposal.
J Med Chem
; 49(25): 7545-8, 2006 Dec 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-17149884
5.
Reproducible production of a PEGylated dual-acting peptide for diabetes.
AAPS J
; 9(2): E227-34, 2007 Jun 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-17907763
6.
Design of a long acting peptide functioning as both a glucagon-like peptide-1 receptor agonist and a glucagon receptor antagonist.
J Biol Chem
; 281(18): 12506-15, 2006 May 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-16505481